Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden
Therapeutic Advances in Respiratory Disease · 2024
DOI: 10.1177/17534666241254090 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2024. Verfasst von Mahasin Al Shakirchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stockholm CF Centre, Karolinska University Hospital Huddinge, Stockholm, Department of Clinical Science, Intervention and Technology, Sweden. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Drug Combinations. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hjärt-Lungfonden, Stiftelsen Riksförbundet Cystisk Fibros Forskningsfond.
Abstract (Originalsprache)
Background
A significant decline in pulmonary exacerbation rates has been reported in CF patients homozygous for F508del treated with lumacaftor/ivacaftor. However, it is still unclear whether this reduction reflects a diminished microbiological burden.
Objectives
The aim of this study was to determine the impact of lumacaftor/ivacaftor on the bacterial and fungal burden.
Design
The study is a prospective multicenter cohort study including 132 CF patients homozygous for F508del treated with lumacaftor/ivacaftor.
Methods
Clinical parameters as well as bacterial and fungal outcomes 1 year after initiation of lumacaftor/ivacaftor were compared to data from 2 years prior to initiation of the treatment. Changes in the slope of the outcomes before and after the onset of treatment were assessed.
Results
Lung function measured as ppFEV1 ( p < 0.001), body mass index (BMI) in adults ( p < 0.001), and BMI z-score in children ( p = 0.007) were improved after initiation of lumacaftor/ivacaftor. In addition, the slope of the prevalence of Streptococcus pneumoniae ( p = 0.007) and Stenotrophomonas maltophilia ( p < 0.001) shifted from positive to negative, that is, became less prevalent, 1 year after treatment, while the slope for Candida albicans ( p = 0.009), Penicillium spp ( p = 0.026), and Scedosporium apiospermum ( p < 0.001) shifted from negative to positive.
Conclusion
The current study showed a significant improvement in clinical parameters and a reduction of some of CF respiratory microorganisms 1 year after starting with lumacaftor/ivacaftor. However, no significant changes were observed for Pseudomonas aeruginosa, Staphylococcus aureus, or Aspergillus fumigatus, key pathogens in the CF context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stockholm CF Centre, Karolinska University Hospital Huddinge, Stockholm, Department of Clinical Science, Intervention and Technology, Sweden.
- Division of Pediatrics, Karolinska Institutet, Alfred Nobels Allé 8, Stockholm 171 77, Sweden.
- Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Stockholm CF Centre, Karolinska University Hospital Huddinge, Stockholm, Sweden.
- Department of Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska Institutet, Stockholm, Sweden.
- Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Mahasin Al Shakirchi
Förderung
- Hjärt-Lungfonden
- Stiftelsen Riksförbundet Cystisk Fibros Forskningsfond
Zitieren
APA
Al Shakirchi, M., Sorjonen, K., Hjelte, L., Klingspor, L., Bergman, P., Ericson, P., Svedberg, M., Lindberg, U., Hansen, C., & Monestrol, I. (2024). Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241254090
Vancouver
Al Shakirchi M, Sorjonen K, Hjelte L, Klingspor L, Bergman P, Ericson P, et al. Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden. Therapeutic Advances in Respiratory Disease. 2024. doi:10.1177/17534666241254090
BibTeX
@article{AlShakirchi2024,
author = {Al Shakirchi, Mahasin and Sorjonen, Kimmo and Hjelte, Lena and Klingspor, Lena and Bergman, Peter and Ericson, Petrea and Svedberg, Marcus and Lindberg, Ulrika and Hansen, Christine and Monestrol, Isabelle de},
title = {Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2024},
doi = {10.1177/17534666241254090}
}
EUVIMED